News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioAlliance Strengthens the Protection of Livatag(R) (doxorubicin Transdrug(TM) with the Grant of a European Patent


7/12/2011 9:34:07 AM

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to specialty and orphan oncology products, today announces the grant of a European patent protecting its Transdrug™ nanotechnology. This new industrial property notably covers Livatag®, the first product of its « Orphan oncology products » portfolio until 2023.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES